
    
      Approximately 60 subjects will be enrolled in 1 of 2 cohorts. Following a review of Cohort 1
      safety and tolerability data, subjects will then be enrolled into Cohort 2, to explore
      additional doses. Dose escalation will occur in both cohorts. There will be 18 visits over a
      6-week period.
    
  